# Antonio Bertolotto

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5770827/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 255 papers | 12,807 citations | 26567 56 h-index | 29081 104 g-index |
| 262 all docs | 262 docs citations | 262 times ranked | 11058 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 402-415. | 13.9 | 1,983 |
| 2 | Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1503-1511. | 6.3 | 551 |
| 3 | Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789. | 2.8 | 370 |
| 4 | Recommendations to standardize preanalytical confounding factors in Alzheimerâ€™s and Parkinsonâ€™s disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430. | 0.6 | 280 |
| 5 | The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921. | 1.5 | 274 |
| 6 | Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 371, 2085-2092. | 6.3 | 265 |
| 7 | Cognitive and psychosocial features of childhood and juvenile MS. Neurology, 2008, 70, 1891-1897. | 1.5 | 251 |
| 8 | Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015. | 0.9 | 228 |
| 9 | Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal, 2012, 18, 143-152. | 1.4 | 220 |
| 10 | Guillain-Barrè•syndrome. Neurology, 2003, 60, 1146-1150. | 1.5 | 214 |
| 11 | Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 740-750. | 4.9 | 188 |
| 12 | Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis. Archives of Neurology, 2002, 59, 1406-12. | 4.9 | 180 |
| 13 | Persistent neutralizing antibodies abolish the interferon Î² bioavailability in MS patients. Neurology, 2003, 60, 634-639. | 1.5 | 173 |
| 14 | Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€“remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788. | 1.4 | 172 |
| 15 | Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells.. Journal of Cell Biology, 1991, 114, 855-863. | 2.3 | 166 |
| 16 | In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain, 2001, 124, 2540-2549. | 3.7 | 163 |
| 17 | Neutralizing antibodies reduce the efficacy of Î²IFN during treatment of multiple sclerosis. Neurology, 2004, 62, 2031-2037. | 1.5 | 156 |
| 18 | In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain, 2007, 130, 2211-2219. | 3.7 | 141 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4923-4928. | 1.8 | 140 |
| 20 | Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 148-153. | 0.9 | 136 |
| 21 | Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809. | 1.4 | 133 |
| 22 | Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1349-1353. | 0.9 | 128 |
| 23 | Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain, 2006, 129, 2628-2634. | 3.7 | 122 |
| 24 | Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Multiple Sclerosis Journal, 2012, 18, 835-842. | 1.4 | 115 |
| 25 | Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. NeuroImage, 2005, 24, 1139-1146. | 2.1 | 106 |
| 26 | Interferon Î² neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology, 2000, 48, 95-100. | 2.0 | 99 |
| 27 | Corpus callosum damage and cognitive dysfunction in benign MS. Human Brain Mapping, 2009, 30, 2656-2666. | 1.9 | 99 |
| 28 | Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Multiple Sclerosis Journal, 2006, 12, 47-57. | 1.4 | 92 |
| 29 | Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1141-1143. | 0.9 | 89 |
| 30 | Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77. | 1.4 | 89 |
| 31 | Risk of cancer in patients with Guillain-Barrï¿½ syndrome (GBS). Journal of Neurology, 2004, 251, 321-326. | 1.8 | 86 |
| 32 | Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology, 2008, 71, 1521-1526. | 1.5 | 85 |
| 33 | Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology, 2008, 70, 1119-1127. | 1.5 | 84 |
| 34 | Evaluation of bioavailability of three types of IFNÎ² in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. Journal of Immunological Methods, 2001, 256, 141-152. | 0.6 | 83 |
| 35 | Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e498. | 3.1 | 81 |
| 36 | The proteoglycan chondroitin sulfate is present in a subpopulation of cultured astrocytes and in their precursors. Developmental Biology, 1987, 123, 282-285. | 0.9 | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Chondroitin sulfate proteoglycan surrounds a subset of human and rat CNS neurons. Journal of Neuroscience Research, 1991, 29, 225-234. | 1.3 | 77 |
| 38 | Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286. | 3.7 | 76 |
| 39 | Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 377-381. | 0.9 | 73 |
| 40 | I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Multiple Sclerosis Journal, 2007, 13, 490-501. | 1.4 | 72 |
| 41 | Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233. | 1.4 | 72 |
| 42 | Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis. PLoS ONE, 2010, 5, e8962. | 1.1 | 69 |
| 43 | Immunogenicity of interferon beta: differences among products. Journal of Neurology, 2004, 251, II15-II24. | 1.8 | 68 |
| 44 | Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199. | 0.9 | 68 |
| 45 | Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895. | 1.5 | 68 |
| 46 | Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. European Cytokine Network, 2001, 12, 56-61. | 1.1 | 68 |
| 47 | Immunohistochemical mapping of perineuronal nets containing chondroitin unsulfate proteoglycan in the rat central nervous system. Cell and Tissue Research, 1996, 283, 283-295. | 1.5 | 66 |
| 48 | A Magnetic Resonance Imaging Voxel-Based Morphometry Study of Regional Gray Matter Atrophy in Patients With Benign Multiple Sclerosis. Archives of Neurology, 2008, 65, 1223-30. | 4.9 | 64 |
| 49 | Neutralizing antibodies against IFN-Â in multiple sclerosis: antagonization of IFN-Â mediated suppression of MMPs. Brain, 2004, 127, 259-268. | 3.7 | 63 |
| 50 | Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. Journal of Immunological Methods, 2007, 321, 19-31. | 0.6 | 63 |
| 51 | Measurement of MxA mRNA or protein as a biomarker of IFNÎ² bioactivity. Neurology, 2003, 61, S24-6. | 1.5 | 63 |
| 52 | Chondroitin 4-sulfate proteoglycan forms an extracellular network in human and rat central nervous system. Journal of the Neurological Sciences, 1990, 100, 113-123. | 0.3 | 62 |
| 53 | PML risk stratification using anti-JCV antibody index and L-selectin. Multiple Sclerosis Journal, 2016, 22, 1048-1060. | 1.4 | 62 |
| 54 | Extracellular matrix of cultured glial cells: Selective expression of chondroitin 4-sulfate by type-2 astrocytes and their progenitors. Experimental Cell Research, 1990, 187, 211-223. | 1.2 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Variable responses to rituximab treatment in neuromyelitis optica (Devicâ€™s disease). Neurological Sciences, 2007, 28, 209-211. | 0.9 | 60 |
| 56 | Selective expression of the Met/HGF receptor in human central nervous system microglia. Oncogene, 1993, 8, 219-22. | 2.6 | 59 |
| 57 | Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132. | 0.9 | 57 |
| 58 | Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurological Sciences, 2005, 26, s183-s186. | 0.9 | 56 |
| 59 | The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626. | 1.4 | 56 |
| 60 | Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. Journal of Neuroimmunology, 2005, 158, 195-203. | 1.1 | 55 |
| 61 | The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070. | 1.4 | 53 |
| 62 | Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Multiple Sclerosis Journal, 2010, 16, 1360-1366. | 1.4 | 53 |
| 63 | Aquaporin-4 antibody titration in NMO patients treated with rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e317. | 3.1 | 53 |
| 64 | Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1294-1299. | 0.9 | 52 |
| 65 | Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinsonâ€™s and Alzheimerâ€™s Disease Patients. Neurotoxicity Research, 2016, 30, 338-344. | 1.3 | 51 |
| 66 | Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain, 2017, 140, 2814-2819. | 3.7 | 51 |
| 67 | Neutralising antibodies to interferon Î² in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837. | 1.8 | 48 |
| 68 | Collagenase in the immunohistochemical demonstration of laminin, fibronectin and factor VII/RAg in nervous tissue after fixation. Histochemistry, 1984, 80, 157-163. | 1.9 | 45 |
| 69 | Monoclonal antibodies to keratan sulfate immunolocalize ramified microglia in paraffin and cryostat sections of rat brain.. Journal of Histochemistry and Cytochemistry, 1993, 41, 481-487. | 1.3 | 44 |
| 70 | High-dose glucocorticoids increase serum levels of soluble IL-6 receptor Î± and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. European Journal of Endocrinology, 2006, 154, 745-751. | 1.9 | 44 |
| 71 | Presence and Significant Determinants of Cognitive Impairment in a Large Sample of Patients with Multiple Sclerosis. PLoS ONE, 2013, 8, e69820. | 1.1 | 44 |
| 72 | Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurological Sciences, 2011, 32, 1223-1231. | 0.9 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. Neurology and Therapy, 2015, 4, 147-157. | 1.4 | 43 |
| 74 | Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470. | 0.9 | 42 |
| 75 | Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517. | 1.4 | 42 |
| 76 | Immunohistochemical localization of chondroitin sulfate in normal and pathological human muscle. Journal of the Neurological Sciences, 1986, 73, 233-244. | 0.3 | 41 |
| 77 | Loss of Braking Signals During Inflammation. Archives of Neurology, 2011, 68, 879. | 4.9 | 40 |
| 78 | Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis Journal, 2014, 20, 577-587. | 1.4 | 40 |
| 79 | A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 26-30. | 0.9 | 38 |
| 80 | Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407. | 1.4 | 38 |
| 81 | Cerebrospinal fluid findings in Devic?s neuromyelitis optica. Neurological Sciences, 2004, 25, s368-s370. | 0.9 | 37 |
| 82 | Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Current Opinion in Neurology, 2004, 17, 241-246. | 1.8 | 37 |
| 83 | Expression and regulation of IFNÎ±/Î² receptor in IFNÎ²-treated patients with multiple sclerosis. Neurology, 2008, 71, 1940-1947. | 1.5 | 36 |
| 84 | A methodological reappraisal of non invasive high voltage electrical stimulation of lumbosacral nerve roots. Clinical Neurophysiology, 2011, 122, 2071-2080. | 0.7 | 36 |
| 85 | Effects of Isoxazolo-Pyridinone 7e, a Potent Activator of the Nurr1 Signaling Pathway, on Experimental Autoimmune Encephalomyelitis in Mice. PLoS ONE, 2014, 9, e108791. | 1.1 | 36 |
| 86 | Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology, 2021, 96, . | 1.5 | 36 |
| 87 | Cytokine profiles show heterogeneity of interferon-Î² response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202. | 3.1 | 34 |
| 88 | Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739. | 2.8 | 34 |
| 89 | Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. Journal of Neurology, 2018, 265, 1850-1859. | 1.8 | 33 |
| 90 | Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. Journal of Neuroimmunology, 2009, 217, 74-79. | 1.1 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis. Archives of Neurology, 2010, 67, 402. | 4.9 | 31 |
| 92 | Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS ONE, 2016, 11, e0153466. | 1.1 | 31 |
| 93 | Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316. | 0.9 | 30 |
| 94 | Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology, 2014, 83, 1210-1216. | 1.5 | 30 |
| 95 | Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurological Sciences, 2017, 38, 217-224. | 0.9 | 30 |
| 96 | Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858. | 0.9 | 30 |
| 97 | Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2017, 8, 321. | 2.2 | 30 |
| 98 | Concomitant brain arterial and venous thrombosis in a COVIDâ€19 patient. European Journal of Neurology, 2020, 27, e38-e39. | 1.7 | 30 |
| 99 | Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. Journal of NeuroImmune Pharmacology, 2012, 7, 665-672. | 2.1 | 29 |
| 100 | The Effectiveness of a Body-Affective Mindfulness Intervention for Multiple Sclerosis Patients with Depressive Symptoms: A Randomized Controlled Clinical Trial. Frontiers in Psychology, 2017, 8, 2083. | 1.1 | 29 |
| 101 | In vivo silencing of miRâ€125aâ€3p promotes myelin repair in models of white matter demyelination. Glia, 2020, 68, 2001-2014. | 2.5 | 29 |
| 102 | Three years of experience: the Italian registry and safety data update. Neurological Sciences, 2011, 31, 295-297. | 0.9 | 28 |
| 103 | NURR1 deficiency is associated to ADHD-like phenotypes in mice. Translational Psychiatry, 2019, 9, 207. | 2.4 | 28 |
| 104 | Transforming growth factor Î²1 (TGFÎ²1) mRNA level correlates with magnetic resonance imaging disease activity in Multiple Sclerosis patients. Neuroscience Letters, 1999, 263, 21-24. | 1.0 | 27 |
| 105 | The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNÎ² exposure in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 578-585. | 1.4 | 27 |
| 106 | Glycosaminoglycan changes in human gliomas. A biochemical study. Journal of Neuro-Oncology, 1986, 4, 43-48. | 1.4 | 26 |
| 107 | 5D4 keratan sulfate epitope identifies a subset of ramified microglia in normal central nervous system parenchyma. Journal of Neuroimmunology, 1998, 85, 69-77. | 1.1 | 26 |
| 108 | Nurr1 reduction influences the onset of chronic EAE in mice. Inflammation Research, 2015, 64, 841-844. | 1.6 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726. | 4.5 | 26 |
| 110 | Laminin and fibronectin distribution in normal and pathological human muscle. Journal of the Neurological Sciences, 1983, 60, 377-382. | 0.3 | 25 |
| 111 | Monocytes and CD4 + T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis. Journal of Neuroimmunology, 2014, 272, 99-102. | 1.1 | 25 |
| 112 | High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurology and Therapy, 2017, 6, 145-152. | 1.4 | 25 |
| 113 | Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. Neurological Sciences, 2003, 24, 130-133. | 0.9 | 24 |
| 114 | No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. European Journal of Neurology, 2015, 22, 585-587. | 1.7 | 24 |
| 115 | No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon Î²1b therapy in relapsingâ€“remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173. | 1.4 | 24 |
| 116 | Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. Journal of Neurology, 2004, 251, II31-9. | 1.8 | 23 |
| 117 | One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. Journal of Neurology, 2011, 258, 895-903. | 1.8 | 23 |
| 118 | Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis. PLoS ONE, 2015, 10, e0129291. | 1.1 | 23 |
| 119 | Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. Journal of Neuroinflammation, 2015, 12, 146. | 3.1 | 23 |
| 120 | Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Multiple Sclerosis Journal, 2015, 21, 1713-1722. | 1.4 | 23 |
| 121 | A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. Journal of Neuroimmunology, 2016, 292, 34-39. | 1.1 | 23 |
| 122 | A20 in Multiple Sclerosis and Parkinsonâ€™s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. Neurotoxicity Research, 2017, 32, 1-7. | 1.3 | 23 |
| 123 | Anti-interferon-Î² neutralising activity is not entirely mediated by antibodies. Journal of Neuroimmunology, 2007, 192, 198-205. | 1.1 | 22 |
| 124 | In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 789-794. | 1.4 | 22 |
| 125 | Interferon-Î² bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Multiple Sclerosis Journal, 2009, 15, 212-218. | 1.4 | 22 |
| 126 | Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2013, 20, 240-246. | 0.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimotoâ€™s Thyroiditis. Frontiers in Immunology, 2018, 9, 311. | 2.2 | 21 |
| 128 | Glycosaminoglycans in human cerebral tumors. Acta Neuropathologica, 1982, 57, 299-305. | 3.9 | 20 |
| 129 | Keratan sulphate is a marker of differentiation of ramified microglia. Developmental Brain Research, 1995, 86, 233-241. | 2.1 | 20 |
| 130 | Italian studies on early-onset multiple sclerosis: the present and the future. Neurological Sciences, 2004, 25, s346-s349. | 0.9 | 20 |
| 131 | Acuteâ€phase proteins investigation based on lectins affinity capture prior to 2â€ÐE separation: Application to serum from multiple sclerosis patients. Electrophoresis, 2010, 31, 2882-2893. | 1.3 | 20 |
| 132 | Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clinical Immunology, 2017, 181, 83-88. | 1.4 | 20 |
| 133 | Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453. | 1.7 | 20 |
| 134 | Congenital Muscular Dystrophy Associated with Familial Junctional Epidermolysis Bullosa Letalis. European Neurology, 1993, 33, 454-460. | 0.6 | 19 |
| 135 | Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial. Trials, 2012, 13, 183. | 0.7 | 19 |
| 136 | Evaluation of a Multiparametric Immunofluorescence Assay for Standardization of Neuromyelitis Optica Serology. PLoS ONE, 2012, 7, e38896. | 1.1 | 19 |
| 137 | Glycosaminoglycans (GASs) in human cerebral tumors. Acta Neuropathologica, 1982, 58, 115-119. | 3.9 | 18 |
| 138 | Evaluation of IFNÎ± bioavailability by MxA mRNA in HCV patients. Journal of Immunological Methods, 2002, 262, 187-190. | 0.6 | 18 |
| 139 | Qualitative and quantitative analysis of antibody response against IFNÎ² in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 738-746. | 1.4 | 18 |
| 140 | Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. Journal of Immunological Methods, 2008, 336, 119-126. | 0.6 | 18 |
| 141 | Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 132. | 3.1 | 18 |
| 142 | The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice. Cephalalgia, 2016, 36, 131-138. | 1.8 | 18 |
| 143 | Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurological Sciences, 2005, 26, s200-s203. | 0.9 | 17 |
| 144 | Interferon-beta responders and non-responders. A biological approach. Neurological Sciences, 2008, 29, 216-217. | 0.9 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Implications of neutralising antibodies on therapeutic efficacy. Journal of the Neurological Sciences, 2009, 277, S29-S32. | 0.3 | 17 |
| 146 | Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358. | 0.9 | 17 |
| 147 | Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. Multiple Sclerosis and Related Disorders, 2017, 14, 51-55. | 0.9 | 17 |
| 148 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology, 2019, 10, 253. | 1.1 | 17 |
| 149 | The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. Neurological Sciences, 2009, 30, 163-165. | 0.9 | 16 |
| 150 | Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 | 0.9 | 16 |
| 151 | Evaluation of the impact of neutralizing antibodies on IFNÎ² response. Clinica Chimica Acta, 2015, 449, 31-36. | 0.5 | 16 |
| 152 | Biological monitoring of IFN-Î² therapy in Multiple Sclerosis. Cytokine and Growth Factor Reviews, 2015, 26, 241-248. | 3.2 | 16 |
| 153 | Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue. Frontiers in Immunology, 2019, 10, 1935. | 2.2 | 16 |
| 154 | Morphological and biochemical investigations of mitral valve endocardiosis in pigs. Research in Veterinary Science, 1997, 62, 121-125. | 0.9 | 15 |
| 155 | Necrotizing skin lesions and NA Bs development in a multiple sclerosis patient treated with IFNÎ² 1b. Multiple Sclerosis Journal, 2003, 9, 420-423. | 1.4 | 15 |
| 156 | Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?. Acta Neurologica Scandinavica, 2004, 109, 61-65. | 1.0 | 15 |
| 157 | Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapyâ€™s Adherence, Hospital Reliabilityâ€™s Perception, and Services Provided Quality. Multiple Sclerosis International, 2014, 2014, 1-9. | 0.4 | 15 |
| 158 | The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurology, 2016, 16, 7. | 0.8 | 15 |
| 159 | A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-Î²1a using RebiSmartâ„¢â€"the FUTURE study. Neurological Sciences, 2017, 38, 1999-2005. | 0.9 | 15 |
| 160 | NURR1 Impairment in Multiple Sclerosis. International Journal of Molecular Sciences, 2019, 20, 4858. | 1.8 | 15 |
| 161 | Immunohistochemical study of chondroitin sulfate in human gliomas. Acta Neuropathologica, 1986, 72, 189-196. | 3.9 | 14 |
| 162 | The role of fatigue in the associations between exercise and psychological health in Multiple Sclerosis: Direct and indirect effects. Mental Health and Physical Activity, 2013, 6, 87-94. | 0.9 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients. Quality of Life Research, 2015, 24, 2173-2182. | 1.5 | 14 |
| 164 | Anti-inflammatory genes associated with multiple sclerosis: A gene expression study. Journal of Neuroimmunology, 2015, 279, 75-78. | 1.1 | 14 |
| 165 | The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, . | 1.1 | 14 |
| 166 | Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurological Sciences, 2017, 38, 231-236. | 0.9 | 14 |
| 167 | Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. Journal of the Neurological Sciences, 2005, 237, 5-11. | 0.3 | 13 |
| 168 | Anal sphincter dysfunction in multiple sclerosis: an observation manometric study. Open Medicine (Poland), 2016, 11, 509-517. | 0.6 | 13 |
| 169 | Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Therapeutic Drug Monitoring, 2017, 39, 339-343. | 1.0 | 13 |
| 170 | Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. Multiple Sclerosis and Related Disorders, 2021, 54, 103090. | 0.9 | 13 |
| 171 | Comparison of Three PCR Assays for the Evaluation of Interferon-?? Biological Activity in Patients with Multiple Sclerosis. Molecular Diagnosis and Therapy, 2004, 8, 185-194. | 1.3 | 13 |
| 172 | Disappearance of theVicia villosa-positivity from the perineuronal net containing chondroitin proteoglycan after chondroitinase digestion. Brain Research, 1995, 673, 344-348. | 1.1 | 12 |
| 173 | Quantitative PCR Reveals Increased Levels of Tumor Necrosis Factor-alpha mRNA in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients During Relapses. Journal of Interferon and Cytokine Research, 1999, 19, 575-581. | 0.5 | 12 |
| 174 | Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. Neurological Sciences, 2008, 29, 185-187. | 0.9 | 12 |
| 175 | Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsingâ€“Remitting Multiple Sclerosis Patients. Neurology and Therapy, 2020, 9, 197-203. | 1.4 | 12 |
| 176 | Cellulose acetate electrophoresis of glycosaminoglycans in the central nervous system. Electrophoresis, 1984, 5, 97-101. | 1.3 | 11 |
| 177 | Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. Neurological Sciences, 2005, 26, s213-s214. | 0.9 | 11 |
| 178 | Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2007, 69, 1552-1553. | 1.5 | 11 |
| 179 | Italian national guidelines for the screening of gestational diabetes: Time for a critical appraisal?. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 717-722. | 1.1 | 11 |
| 180 | eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866. | 1.4 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Acute muscle necrosis after chronic overdosage of phenformin and fenfluramine. Muscle and Nerve, 1978, 1, 245-247. | 1.0 | 10 |
| 182 | Letters to the Editor. Muscle and Nerve, 1981, 4, 176-178. | 1.0 | 10 |
| 183 | Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. Neurological Sciences, 2012, 33, 863-867. | 0.9 | 10 |
| 184 | A new neurophysiological approach to assess central motor conduction damage to proximal and distal muscles of lower limbs. Clinical Neurophysiology, 2014, 125, 133-141. | 0.7 | 10 |
| 185 | Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. Frontiers in Human Neuroscience, 2016, 10, 282. | 1.0 | 10 |
| 186 | Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. Journal of Immunological Methods, 2017, 445, 53-58. | 0.6 | 10 |
| 187 | Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report. Neurological Sciences, 2021, 42, 25-28. | 0.9 | 10 |
| 188 | PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944. | 1.8 | 10 |
| 189 | Biochemical and histochemical evaluation of glycosaminoglycans in brain tumors induced in rats by nitrosourea derivatives. Journal of Neuro-Oncology, 1983, 1, 299-306. | 1.4 | 9 |
| 190 | Chondroitin, chondroitin 6-sulphate, chondroitin 4-sulphate and dermatan sulphate proteoglycans in normal and pathological human muscle. Journal of the Neurological Sciences, 1987, 81, 247-259. | 0.3 | 9 |
| 191 | Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. Multiple Sclerosis Journal, 2014, 20, 889-891. | 1.4 | 9 |
| 192 | Overexpression of the ubiquitinâ€editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation. Brain Pathology, 2021, 31, 283-296. | 2.1 | 9 |
| 193 | Exposure to fine particulate matter (PM2.5) hampers myelin repair in a mouse model of white matter demyelination. Neurochemistry International, 2021, 145, 104991. | 1.9 | 9 |
| 194 | Clinical Aspects of Immunogenicity to Biopharmaceuticals. , 2008, , 27-56. | | 9 |
| 195 | Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097213. | 0.5 | 9 |
| 196 | Epidemiology of Duchenne muscular dystrophy in the province of Turin. Italian Journal of Neurological Sciences, 1981, 2, 81-84. | 0.1 | 8 |
| 197 | Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Neurological Sciences, 2008, 29, 227-229. | 0.9 | 8 |
| 198 | Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Therapeutic Drug Monitoring, 2017, 39, 308-315. | 1.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. Journal of Nervous and Mental Disease, 2018, 206, 149-151. | 0.5 | 8 |
| 200 | Study of the NR 4A family gene expression in patients with multiple sclerosis treated with Fingolimod. European Journal of Neurology, 2019, 26, 667-672. | 1.7 | 8 |
| 201 | The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. DMM Disease Models and Mechanisms, 2020, 13, . | 1.2 | 8 |
| 202 | Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects. PLoS ONE, 2016, 11, e0155268. | 1.1 | 8 |
| 203 | On the nature of the so-called monstrocellular sarcoma of the brain. Neurosurgery, 1980, 6, 391-7. | 0.6 | 8 |
| 204 | Motor Neuron Disease following Poliomyelitis. European Neurology, 1980, 19, 414-418. | 0.6 | 7 |
| 205 | Glutamate dehydrogenase (GDH) deficiency in different types of progressive hereditary cerebellar ataxia. Acta Neurologica Scandinavica, 1988, 78, 394-400. | 1.0 | 7 |
| 206 | Acute confusional state in HaNDL syndrome (transient headache and neurologic deficits with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 | 0.9 | 7 |
| 207 | Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. Therapeutic Drug Monitoring, 2017, 39, 350-355. | 1.0 | 7 |
| 208 | Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurological Sciences, 2020, 41, 2843-2851. | 0.9 | 7 |
| 209 | Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636. | 1.5 | 7 |
| 210 | Histochemical and Ultrastructural Findings in a Case of Centronuclear Myopathy. European Neurology, 1978, 17, 327-332. | 0.6 | 6 |
| 211 | Mitochondrial abnormalities of late motor neuron degeneration following poliomyelitis and other neurogenic muscular atrophies. Journal of Neurology, 1979, 221, 193-201. | 1.8 | 6 |
| 212 | Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-Î± Therapy. Neurology and Therapy, 2015, 4, 53-60. | 1.4 | 6 |
| 213 | A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2017, 6, 161-173. | 1.4 | 6 |
| 214 | Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. Multiple Sclerosis and Related Disorders, 2020, 46, 102592. | 0.9 | 6 |
| 215 | Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578. | 1.7 | 6 |
| 216 | Osteomalacic myopathy in a case of diffuse nodular lipomatosis of the small bowel. Acta Neurologica Belgica, 1982, 82, 65-71. | 0.5 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | <scp>NURR1</scp>â€deficient mice have ageâ€and sexâ€specific behavioral phenotypes. Journal of Neuroscience Research, 2022, 100, 1747-1754. | 1.3 | 6 |
| 218 | CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. Journal of Neuroimmunology, 2014, 277, 127-133. | 1.1 | 5 |
| 219 | Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Frontiers in Neurology, 2019, 10, 695. | 1.1 | 5 |
| 220 | Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level. Neuroepidemiology, 2021, 55, 119-125. | 1.1 | 5 |
| 221 | Quantitation of nanogram amounts of glycosaminoglycans in samples containing proteins by a new densitometric method. Electrophoresis, 1985, 6, 35-38. | 1.3 | 4 |
| 222 | Comparison of three PCR assays for the evaluation of interferon-Î² biological activity in patients with multiple sclerosis. Molecular Diagnosis and Therapy, 2004, 8, 185-194. | 1.3 | 4 |
| 223 | The still under-investigated role of cognitive deficits in PML diagnosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, . | 1.1 | 4 |
| 224 | Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study.. Multiple Sclerosis and Related Disorders, 2018, 24, 107-112. | 0.9 | 4 |
| 225 | Assessing measurement invariance of MSQOL-54 across Italian and English versions. Quality of Life Research, 2020, 29, 783-791. | 1.5 | 4 |
| 226 | Quality of Life Improves with Alemtuzumab Over 6ÂYears in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2020, 9, 443-457. | 1.4 | 4 |
| 227 | TNFAIP3 Deficiency Affects Monocytes, Monocytes-Derived Cells and Microglia in Mice. International Journal of Molecular Sciences, 2020, 21, 2830. | 1.8 | 4 |
| 228 | Sporadic oculopharyngeal myopathy with abnormal mitochondria. Acta Neurologica Belgica, 1978, 78, 373-82. | 0.5 | 4 |
| 229 | The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line. Current Issues in Molecular Biology, 2022, 44, 1247-1256. | 1.0 | 4 |
| 230 | On the Nature of the So-Called Monstrocellular Sarcoma of the Brain. Neurosurgery, 1980, 6, 391-397. | 0.6 | 3 |
| 231 | Myoglobinuria: presentation of personal cases and review of the literature. Italian Journal of Neurological Sciences, 1981, 2, 275-281. | 0.1 | 3 |
| 232 | Progressive multifocal leukoencephalopathy in Good's syndrome. International Journal of Infectious Diseases, 2010, 14, e367-e368. | 1.5 | 3 |
| 233 | A First Phenotypic and Functional Characterization of Placental Extracellular Vesicles from Women with Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 2875. | 1.8 | 3 |
| 234 | Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of International Medical Research, 2008, 36, 204-8; author reply 208-10. | 0.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes. Molecular Biology Reports, 2022, 49, 4709-4718. | 1.0 | 3 |
| 236 | Two-dimensional immunoelectrophyoresis of unconcentrated cerebrospinal fluid. Journal of the Neurological Sciences, 1978, 37, 199-203. | 0.3 | 2 |
| 237 | Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-Î³ and interleukin-4 response. Multiple Sclerosis Journal, 2012, 18, 1484-1492. | 1.4 | 2 |
| 238 | Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, . | 1.1 | 2 |
| 239 | The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Global & Regional Health Technology Assessment, 2019, 2019, 228424031983852. | 0.2 | 2 |
| 240 | Viability of a MSQOL-54 general health-related quality of life score using bifactor model. Health and Quality of Life Outcomes, 2021, 19, 224. | 1.0 | 2 |
| 241 | Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis. Journal of Trace Elements in Medicine and Biology, 2021, 68, 126831. | 1.5 | 2 |
| 242 | Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor. Frontiers in Immunology, 2021, 12, 775151. | 2.2 | 2 |
| 243 | Development of a shortened version of the MSQOL-54 using factor analysis and item response theory. Journal of the Neurological Sciences, 2015, 357, e318-e319. | 0.3 | 1 |
| 244 | Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. Neurological Sciences, 2016, 37, 2019-2023. | 0.9 | 1 |
| 245 | PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL) Tj ETQq1 1 0.784314 rg | 0.1 | 1 |
| 246 | The reliability of objective fatigue measures in Multiple Sclerosis Patients. Biomedical Signal Processing and Control, 2020, 56, 101696. | 3.5 | 1 |
| 247 | Coverage of the requirements of first and second level stroke unit in Italy. Neurological Sciences, 2021, 42, 1073-1079. | 0.9 | 1 |
| 248 | Successful pregnancy and disease outcomes in a NMOSD patient treated with tocilizumab. Neuroimmunology Reports, 2021, 1, 100014. | 0.2 | 1 |
| 249 | Biochemical, histochemical and immunohistochemical study of glycosaminoglycans in human meningiomas. Basic and Applied Histochemistry, 1989, 33, 239-49. | 0.1 | 1 |
| 250 | Induction of brain tumors by transplagental enu: Correlation between neurocytogenesis and tumor development. International Journal of Developmental Neuroscience, 1985, 3, 431-431. | 0.7 | 0 |
| 251 | Acknowledgement to Authors, Referees, and Readers. Neurology and Therapy, 2018, 7, 395-396. | 1.4 | 0 |
| 252 | Authorsâ€™ Response to the Letter to the Editor Regarding: A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2018, 7, 391-393. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Acknowledgement to Authors, Referees and Readers 2019. Neurology and Therapy, 2019, 8, 513-515. | 1.4 | 0 |
| 254 | Neurology and Therapy: Looking Back on 2018 and Forward to 2019. Neurology and Therapy, 2019, 8, 1-3. | 1.4 | 0 |
| 255 | Quality control in biobank samples: The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes. Journal of the Neurological Sciences, 2021, 429, 119937. | 0.3 | 0 |